Skip to content

The randomized double-blinded controlled trial of Kparviflora versus Betahistine in treating chronic vertigenous patients

The randomized, double-blinded, controlled trial of Kaempferia parviflora versus Betahistine in treating chronic vertigenous patients

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220829001
Enrollment
120
Registered
2022-08-29
Start date
2023-03-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic vertigo chronic dizziness vertigo dizziness chronic vertigo

Interventions

Kparviflora 180 mg/day with Placebo Betahistine 48 mg/day per oral for 84 days,Placebo KParviflora 180 mg/day with Betahistine 48 mg/day per oral for 84 days
Active Comparator Drug,Active Comparator Drug
K.parviflora,Betahistine

Sponsors

Argricultural Research Development Agency (Public Organization)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Individual who suffered from chronic dizziness longer than 1 month with DHI-T score over 18 2. Age 18-75 years 3. Individual who are willing and able to comply with protocol until the end of project 4. Able to read and write in Thai

Exclusion criteria

Exclusion criteria: 1. Individual who had been diagnosed with Benign Paroxysmal Positional Vertigo or Vestibular Migraine or Height Vertigo or Orthostatic Hypotension or Mental or psychiatric problem 2. Individual with abnormal proprioception including tremor and hemiplegia paraplegia 3. Individual with cardiac arrythmia 4. Individual who had been treated with and cannot withdraw EGb761 120mg/day or over or Betahistine 36 mg/day or over for longer than 72 hours 5. Individual who currently consume other herbal medicines 6. Individual who currently consume any kind of neurotic suppressor medications 7. Individual with active otitis media or perforation of tympanic membrane 8. Individual with abnormal liver and kidney function (GFR lower than 60) 9. Individual who cannot sit or stand without assistant 10. Individual with urine pregnancy test positive or in pregnancy condition

Design outcomes

Primary

MeasureTime frame
Dizziness Handicap Inventory score (DHI-T) Pre-dose and at 1,28,56 and 84 day post-start DHI-T score

Secondary

MeasureTime frame
Vestibular function Pre-dose and at 84 day post-dose Posturography,VOR gain Pre-dose and at 84 day post-dose vHIT,Blood flow perfusion Pre-dose and at 56 days post-dose Optical coherence tomography angiography

Countries

Thailand

Contacts

Public ContactKwanchanok Yimtae

Khon Kaen University

kwayim@kku.ac.th6643363565

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026